Diabetic Peripheral Neuropathy - Pipeline Insight, 2026

DelveInsight's, "Diabetic Peripheral Neuropathy - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Diabetic Peripheral Neuropathy: Understanding

Diabetic Peripheral Neuropathy: Overview

Diabetic peripheral neuropathy (DPN) refers to the development of peripheral nerve dysfunction in patients with diabetes when other causes are excluded. DPN is a condition in which the nerves of the arms, hands, legs and feet become damaged by diabetes. Peripheral neuropathy can lead to numbness, loss of sensation, and sometimes pain. It is the most frequent complication of diabetes, eventually impacting 60% to 70% of persons with the disease.

DPN develops slowly and insidiously, worsening over time. Signs of the disease may be present even before a person is formally diagnosed with diabetes. Symptoms begin in the longest nerves in the body, affecting the feet first and later the hands in a "stocking-glove" pattern. The symptoms usually spread slowly and evenly up the legs and arms.

DPN encompasses sensory, motor, and autonomic neuropathy. Increased serum glucose leads to insulin resistance, dyslipidemia, and oxidative stress of the endoplasmic reticulum and mitochondria. These processes contribute to accumulating reactive oxygen species (ROS), inflammation, and cellular damage. The infiltrated macrophages inside peripheral nerve cells trigger cytokine and chemokine production, promoting inflammation and nerve fiber damage. In addition, implicated causes of peripheral nerve damage include advanced glycosylation end products and disturbance of hexosamine, protein kinase C, and polymerase pathways. Neurovascular impairment with poor repair processes and endothelial dysfunction also have been implicated.

The exact cause of DPN is not known. Proposed theories include metabolic, neurovascular, and autoimmune pathways have been proposed. Mechanical compression (e.g., carpal tunnel), genetics, and social and lifestyle factors such as chronic alcohol consumption and smoking have all been implicated. Perpetually high blood serum glucose leads to insulin resistance, promoting oxidative stress, inflammation, and cell damage. First, the distal sensory and autonomic nerve fibers are damaged; the damage continues with proximal progression, leading to a gradual loss of protective sensation in the skin and foot joints.

Diagnosis and management of Diabetic Peripheral Neuropathy are primarily based on clinical evaluation, with specialized testing reserved for atypical or severe cases. Diagnosis typically involves assessment of symptoms and neurological examination, while advanced investigations such as nerve conduction studies, electromyography, and intraepidermal nerve fiber density testing (via skin biopsy) are used when symptoms are rapidly progressive, asymmetric, or involve motor weakness. Laboratory tests may be conducted to exclude other causes in persistent or unclear cases. Management is multifaceted, beginning with preventive strategies such as patient education, proper foot care, and regular monitoring, along with strict glycemic control to slow disease progression and potentially improve symptoms. Lifestyle modifications including weight loss, healthy diet, and physical activity are essential components of care. Pharmacological treatment focuses on pain management, with first-line agents including gabapentinoids and duloxetine, followed by antidepressants, topical therapies, and opioids in more severe cases.

"Diabetic Peripheral Neuropathy - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Peripheral Neuropathy pipeline landscape is provided which includes the disease overview and Diabetic Peripheral Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Peripheral Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Peripheral Neuropathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Peripheral Neuropathy.

Diabetic Peripheral Neuropathy Emerging Drugs Chapters

This segment of the Diabetic Peripheral Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Peripheral Neuropathy Emerging Drugs

• Suzetrigine: Vertex Pharmaceuticals Incorporated

Suzetrigine is the first class of non-opioid analgesics that selectively targets and blocks a key mediator in pain signal transmission, NaV1.8, which is expressed in the peripheral nociceptive neurons. Suzetrigine displays a novel mechanism of action. It works in the periphery, where the pain stimulation begins and spreads throughout the body via nociceptors, or pain receptors. Suzetrigine inhibits the pain sensations by dampening the nerve signals from the periphery to the spinal cord. More precisely, it stabilizes the closed state of the sodium channels (the NaV1.8, which is expressed in sensory neurons of the primary human dorsal root ganglion). Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Diabetic Peripheral Neuropathy.

• CagriSema: Novo Nordisk A/S

CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Diabetic Peripheral Neuropathy.

• LX-9211: Lexicon Pharmaceuticals

LX9211 is a potent, highly-selective, small molecule inhibitor of the novel target, adaptor-associated kinase 1 (AAK1). It is being developed by Lexicon Pharmaceuticals for the treatment of neuropathic pain, such as diabetic peripheral neuropathy (DPNP) and postherpetic neuralgia. Preclinical studies have shown that LX-9211 does produce a reduction in nociceptive related behaviors and produces no major adverse effects in rats. Thus, LX-9211 has advanced to clinical trials to assess its safety and efficacy in humans. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Diabetic Peripheral Neuropathy.

Diabetic Peripheral Neuropathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Peripheral Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Diabetic Peripheral Neuropathy
• There are approx. 15+ key companies which are developing the therapies for Diabetic Peripheral Neuropathy. The companies which have their Diabetic Peripheral Neuropathy drug candidates in the most advanced stage, i.e. phase III include, Vertex Pharmaceuticals Incorporated.
• Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Diabetic Peripheral Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Peripheral Neuropathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Peripheral Neuropathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Peripheral Neuropathy drugs.

Diabetic Peripheral Neuropathy Report Insights

• Diabetic Peripheral Neuropathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Peripheral Neuropathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Peripheral Neuropathy drugs?
• How many Diabetic Peripheral Neuropathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Peripheral Neuropathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Peripheral Neuropathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Peripheral Neuropathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vertex Pharmaceuticals Incorporated
• Novo Nordisk A/S
• Lexicon Pharmaceuticals
• Helixmith Co., Ltd.
• Centrexion Therapeutics
• Alcamena Stem Cell Therapeutics
• WinSanTor, Inc.
• Trevena
• Sanodyne Therapeutics, Inc.
• AlgoTx

Key Products

• Suzetrigine
• CagriSema
• LX-9211
• VM202
• CNTX-6016
• ASCT-83
• WST-057
• TRV045
• SNT-001
• ATX-01